Recruiting PHASE2/PHASE3 INTERVENTIONAL 5-arm NCT07047612

ICP-332 in Subjects With Non-segmental Vitiligo

A Phase II/III Randomized, Double-blind, Placebo-controlled, Parallel Group, Adaptive Design, Multi-center Study to Evaluate the Efficacy and Safety of ICP-332 in Subjects With Non-segmental Vitiligo

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.

Conditions Non Segmental Vitiligo

Interventions ICP-332 Placebo Tablets ICP-332 Tablets

Updated 2 times since 2025 Last updated: Aug 5, 2025 Started: May 9, 2025 Primary completion: Apr 30, 2029 Completion: Apr 30, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Non Segmental Vitiligo and is currently actively recruiting participants. Beijing InnoCare Pharma Tech Co., Ltd. leads this study, which shows 2 recorded versions since 2025 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

2 versions recorded

Sep 2025 — Present [monthly]

Recruiting PHASE2/PHASE3
Aug 2025 — Sep 2025 [monthly]

Recruiting PHASE2/PHASE3

First recorded

May 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beijing InnoCare Pharma Tech Co., Ltd.

Data source: Beijing InnoCare Pharma Tech Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beijing, China , Changchun, China , Changsha, China , Chengdu, China , Chongqing, China , Fuzhou, China , Guangzhou, China , Hangzhou, China , Hengyang, China , Jinan, China and 21 more locations